MannKind Corporation (MNKD): Price and Financial Metrics

MannKind Corporation (MNKD): $3.71

0.04 (-1.07%)

POWR Rating

Component Grades








Add MNKD to Watchlist
Sign Up

Industry: Biotech




#34 of 346

in industry

MNKD Price/Volume Stats

Current price $3.71 52-week high $5.75
Prev. close $3.75 52-week low $3.38
Day low $3.64 Volume 2,574,700
Day high $3.79 Avg. volume 2,899,198
50-day MA $3.89 Dividend yield N/A
200-day MA $4.25 Market Cap 1.00B

MNKD Stock Price Chart Interactive Chart >


  • MNKD scores best on the Growth dimension, with a Growth rank ahead of 96.52% of US stocks.
  • The strongest trend for MNKD is in Quality, which has been heading down over the past 177 days.
  • MNKD's current lowest rank is in the Momentum metric (where it is better than 15.96% of US stocks).

MNKD Stock Summary

  • The price/operating cash flow metric for MANNKIND CORP is higher than 97.31% of stocks in our set with a positive cash flow.
  • MNKD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 5.96% of US stocks.
  • As for revenue growth, note that MNKD's revenue has grown 131.61% over the past 12 months; that beats the revenue growth of 96.09% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to MANNKIND CORP, a group of peers worth examining would be DVAX, EVLV, EVBG, LNSR, and EOSE.
  • Visit MNKD's SEC page to see the company's official filings. To visit the company's web site, go to

MNKD Valuation Summary

  • In comparison to the median Healthcare stock, MNKD's price/sales ratio is 208.11% higher, now standing at 5.7.
  • Over the past 235 months, MNKD's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MNKD.

Stock Date P/S P/B P/E EV/EBIT
MNKD 2023-11-20 5.7 -4.0 -32.4 -211.9
MNKD 2023-11-17 5.8 -4.1 -32.7 -213.6
MNKD 2023-11-16 5.5 -3.9 -31.0 -204.9
MNKD 2023-11-15 5.7 -4.0 -32.3 -211.4
MNKD 2023-11-14 5.7 -4.0 -32.1 -210.1
MNKD 2023-11-13 5.4 -3.8 -30.5 -202.3

MNKD Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -102.86%.
  • Its 3 year cash and equivalents growth rate is now at 91.81%.
  • Its year over year price growth rate is now at -23.63%.
Over the past 33 months, MNKD's revenue has gone up $13,188,000.

The table below shows MNKD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 76.226 -90.65 -97.514
2022-06-30 65.612 -77.761 -87.508
2022-03-31 69.998 -67.226 -94.008
2021-12-31 75.442 -61.709 -80.926
2021-09-30 81.37 -49.127 -79.276
2021-06-30 74.511 -47.403 -86.105

MNKD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MNKD has a Quality Grade of C, ranking ahead of 42.97% of graded US stocks.
  • MNKD's asset turnover comes in at 0.384 -- ranking 124th of 680 Pharmaceutical Products stocks.
  • VERU, PLX, and LGND are the stocks whose asset turnover ratios are most correlated with MNKD.

The table below shows MNKD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.384 0.611 -0.321
2021-03-31 0.424 0.627 -0.330
2020-12-31 0.673 0.622 -0.564
2020-09-30 0.673 0.595 -0.391
2020-06-30 0.666 0.529 -0.297
2020-03-31 0.705 0.516 -0.324

MNKD Price Target

For more insight on analysts targets of MNKD, see our MNKD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.17 Average Broker Recommendation 1.33 (Strong Buy)

MannKind Corporation (MNKD) Company Bio

MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. The company was founded in 1991 and is based in Valencia, California.

MNKD Latest News Stream

Event/Time News Detail
Loading, please wait...

MNKD Latest Social Stream

Loading social stream, please wait...

View Full MNKD Social Stream

Latest MNKD News From Around the Web

Below are the latest news stories about MANNKIND CORP that investors may wish to consider to help them evaluate MNKD as an investment opportunity.

Investors in MannKind (NASDAQ:MNKD) have seen solid returns of 115% over the past five years

It hasn't been the best quarter for MannKind Corporation ( NASDAQ:MNKD ) shareholders, since the share price has fallen...

Yahoo | December 3, 2023

MannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Call Transcript

MannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Call Transcript November 7, 2023 MannKind Corporation beats earnings expectations. Reported EPS is $0.01, expectations were $-0.02. Operator: Good afternoon and welcome to the MannKind Corporation 2023 Third Quarter Financial Results Earnings Call. As a reminder, this call is being recorded on November 7th, 2023, and will be available […]

Yahoo | November 8, 2023

MannKind (MNKD) Q3 2023 Earnings Call Transcript

As a reminder, this call is being recorded on November 7, 2023, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call until November 21, 2023. Joining us today from MannKind are Chief Executive Officer Michael Castagna and Chief Financial Officer Steven Binder.

Yahoo | November 8, 2023

MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Yahoo | November 7, 2023

MannKind Corporation Reports 2023 Third Quarter Financial Results

Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2023 Total revenues of $51M; +56% vs. 3Q 20223Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 20223Q 2023 Net income of $2M; Non-GAAP net income of $4M3Q 2023 Tyvaso DPI royalties of $20M; +225% vs. 3Q 20223Q 2023 Endocrine BU net revenues of $18M; Afrezza net revenues +24% vs. 3Q 2022 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the

Yahoo | November 7, 2023

Read More 'MNKD' Stories Here

MNKD Price Returns

1-mo 0.82%
3-mo -15.49%
6-mo -7.94%
1-year -18.82%
3-year 25.76%
5-year 112.00%
YTD -29.60%
2022 20.59%
2021 39.62%
2020 142.64%
2019 21.70%
2018 -54.31%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!